Gene Therapy Market Analysis, Trends, and Scope 2021 to 2022
Gene Therapy Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2023 | US$ 5.11 Billion |
Market Size by 2031 | US$ 25.69 Billion |
Global CAGR (2023 - 2031) | 14.3% |
Historical Data | 2021-2023 |
Forecast period | 2023-2031 |
Segments Covered |
By Vectors
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
Industry Developments and Future Opportunities:
A few initiatives taken by market players operating in the global gene therapy market are listed below:
- In January 2022, Ori Biotech Ltd secured over US$ 100 million in an oversubscribed Series B funding round to introduce an innovative cell and gene therapy manufacturing platform in the market.
- In January 2020, Astellas Pharma Inc. acquired Audentes Therapeutics, Inc. The acquisition enables the combined company to become a global leader in AAV-based genetic medicine.
Competitive Landscape and Key Companies:
The gene therapy market forecast can help stakeholders plan their growth strategies. Novartis AG, Astellas Pharma Inc., Bristol-Myers Squibb Company, Bluebird Bio Inc., CSL Behring, Sanofi, F. Hoffmann-La Roche Ltd, Daiichi Sankyo, Biogen, and Oxford Biomedica are among the prominent players profiled in the gene therapy market report. These companies focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.